PDGFRB and cancer: Although our results show that ponatinib (PDGFRA inhibitor) is more effective than sunitinib (PDGFRB inhibitor) in reducing growth and migration of the cancer cells, both inhibitors were capable of suppressing cell proliferation and migration.